Participated · Series A · Feb 2026

Prenosis develops AI-powered diagnostic and therapeutic tools that tailor care to each patient’s unique biological profile. Its core Immunix platform aggregates deep biological data to create diagnostics such as the Sepsis ImmunoScore, the first FDA-authorized AI test for sepsis. The company aims to commercialize ImmunoScore while continuing to expand its portfolio of biology-based diagnostics. Plans include deploying the platform in up to 40 academic medical centers to establish a precision-medicine clinical-trial network, enabling rapid recruitment of patients with specific biological signatures. Led by CEO Bobby Reddy, Jr., PhD, Prenosis positions itself at the intersection of data science, biology, and clinical practice to improve outcomes in critical conditions. The new capital will accelerate product rollout and broaden clinical integration efforts, supporting the company’s mission to personalize critical-care medicine.

Participated · Series A · Dec 2024

1m has developed a SaaS-based platform purpose-built to help healthcare systems manage financial, operational, and regulatory risk by integrating data, analytics and monitoring tools into existing risk management workflows. The platform delivers timely, high-ROI decision support and anomaly detection, with end-to-end risk assessment workflow tools that reduce administrative burdens. It provides continuously updated, healthcare-specific risk datasets to flag emerging threats and quantifies operating and balance sheet risks for integration with long-term financial and strategic planning. Leadership-friendly dashboards surface risk management program outputs to drive engagement, and the product includes built-in risk mitigation support via proprietary data monitoring and anomaly detection tools. The company is led by former Goldman Sachs healthcare investment bankers Jeff Ellis and Chris Giuliano. 1m plans to use the new funding to expand go-to-market efforts, enhance its intellectual property, and hire technical talent.